292 related articles for article (PubMed ID: 20408601)
1. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.
Qiu Y; Fu AZ; Liu GG; Christensen DB
Appl Health Econ Health Policy; 2010; 8(3):167-77. PubMed ID: 20408601
[TBL] [Abstract][Full Text] [Related]
2. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
[TBL] [Abstract][Full Text] [Related]
3. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
4. Employee costs before and after treatment initiation for bipolar disorder.
Brook RA; Kleinman NL; Rajagopalan K
Am J Manag Care; 2007 Apr; 13(4):179-86. PubMed ID: 17408337
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial.
Revicki DA; Hirschfeld RM; Ahearn EP; Weisler RH; Palmer C; Keck PE
J Affect Disord; 2005 Jun; 86(2-3):183-93. PubMed ID: 15935238
[TBL] [Abstract][Full Text] [Related]
6. The impact of unrecognized bipolar disorders among patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program: a 6-year retrospective analysis.
McCombs JS; Ahn J; Tencer T; Shi L
J Affect Disord; 2007 Jan; 97(1-3):171-9. PubMed ID: 16860396
[TBL] [Abstract][Full Text] [Related]
7. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy.
Qiu Y; Christensen DB; Fu AZ; Liu GG
Curr Med Res Opin; 2009 Feb; 25(2):351-61. PubMed ID: 19192979
[TBL] [Abstract][Full Text] [Related]
9. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
[TBL] [Abstract][Full Text] [Related]
10. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program.
Shi L; Thiebaud P; McCombs JS
J Affect Disord; 2004 Nov; 82(3):373-83. PubMed ID: 15555688
[TBL] [Abstract][Full Text] [Related]
11. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
[TBL] [Abstract][Full Text] [Related]
12. How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.
Valuck RJ; Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R;
Curr Med Res Opin; 2007 Oct; 23(10):2567-76. PubMed ID: 17848204
[TBL] [Abstract][Full Text] [Related]
13. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
Sankaranarayanan J; Puumala SE
Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004.
Sankaranarayanan J; Puumala SE
Curr Med Res Opin; 2007 Jun; 23(6):1375-85. PubMed ID: 17594776
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
19. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
20. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
McCombs JS; Luo M; Johnstone BM; Shi L
Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]